EA200600918A1 - Васе455, вариант альтернативного сплайсинга бета-секретазы человека - Google Patents

Васе455, вариант альтернативного сплайсинга бета-секретазы человека

Info

Publication number
EA200600918A1
EA200600918A1 EA200600918A EA200600918A EA200600918A1 EA 200600918 A1 EA200600918 A1 EA 200600918A1 EA 200600918 A EA200600918 A EA 200600918A EA 200600918 A EA200600918 A EA 200600918A EA 200600918 A1 EA200600918 A1 EA 200600918A1
Authority
EA
Eurasian Patent Office
Prior art keywords
secretase
present
diseases
vase455
man
Prior art date
Application number
EA200600918A
Other languages
English (en)
Inventor
Лоран Дезир
Original Assignee
Игзонхит Терапьютикс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Игзонхит Терапьютикс Са filed Critical Игзонхит Терапьютикс Са
Publication of EA200600918A1 publication Critical patent/EA200600918A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)

Abstract

Настоящее изобретение в общем относится к области генетики, биохимии, медицинской химии и медицины. Более конкретно, настоящее изобретение раскрывает идентификацию варианта гена человека, вовлеченного в невропатологические заболевания, и способы диагностики, профилактики и лечения таких заболеваний и сопутствующих нарушений, а также скрининга терапевтически активных лекарств. Настоящее изобретение касается каталитически активных вариантов β-секретазы (memapsin2, ВАСЕ) и кодирующих их нуклеиновых кислот. Изобретение применимо при идентификации агентов, ингибирующих активность определенной изоформы ВАСЕ, а тем самым и агентов, и способов терапии, влияющих на генезис, развитие или прогрессирование невропатологических заболеваний, в том числе болезни Альцгеймера и деменции (слабоумия).
EA200600918A 2003-11-06 2004-11-05 Васе455, вариант альтернативного сплайсинга бета-секретазы человека EA200600918A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51740103P 2003-11-06 2003-11-06
PCT/IB2004/003897 WO2005045021A1 (en) 2003-11-06 2004-11-05 Bace455, an alternative splice variant of the human beta-secretase

Publications (1)

Publication Number Publication Date
EA200600918A1 true EA200600918A1 (ru) 2006-10-27

Family

ID=34572941

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600918A EA200600918A1 (ru) 2003-11-06 2004-11-05 Васе455, вариант альтернативного сплайсинга бета-секретазы человека

Country Status (9)

Country Link
US (2) US7790864B2 (ru)
EP (1) EP1680505A1 (ru)
JP (1) JP2007510425A (ru)
CN (1) CN1875100A (ru)
AU (1) AU2004288034B2 (ru)
CA (1) CA2543837A1 (ru)
EA (1) EA200600918A1 (ru)
IL (1) IL175137A0 (ru)
WO (1) WO2005045021A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US8772457B2 (en) 2010-11-10 2014-07-08 Genentech, Inc. BACE1 antibodies
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
CN103757102A (zh) * 2013-12-23 2014-04-30 成都艾迪康医学检测实验室有限公司 用于检测b型tel-abl融合基因的方法和寡核苷酸
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20020169304A1 (en) * 1999-12-22 2002-11-14 Matthew R. Kaser Aspartyl proteases

Also Published As

Publication number Publication date
IL175137A0 (en) 2006-09-05
US20100317830A1 (en) 2010-12-16
AU2004288034B2 (en) 2011-07-21
JP2007510425A (ja) 2007-04-26
CN1875100A (zh) 2006-12-06
WO2005045021A1 (en) 2005-05-19
US20070142277A1 (en) 2007-06-21
AU2004288034A1 (en) 2005-05-19
EP1680505A1 (en) 2006-07-19
CA2543837A1 (en) 2005-05-19
US7790864B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
Filser et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions
KR102460518B1 (ko) 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
EA200601494A1 (ru) Имидазольные соединения для лечения нейродегенеративных расстройств
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE475432T1 (de) Arzneimittel für herzversagen
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
BRPI0416361A (pt) métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CN102271669A (zh) 非大脑组织中β-淀粉样肽负载的改性
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
Tomita Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
Wiera et al. Extracellular metalloproteinases in the plasticity of excitatory and inhibitory synapses
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
EA200600918A1 (ru) Васе455, вариант альтернативного сплайсинга бета-секретазы человека
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
WO2006091964A8 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
DE60143608D1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
WO2003093442A3 (en) Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
Diniz et al. Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by amyloid‐β (Aβ) oligomers